Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Albert C. Koong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9824-1643; OpenAlex author ID A5071185138; NIH RePORTER profile ID 1939997. Sources: ClinicalTrials.gov.

Their work

Papers
63 (first author 4, last author 6)
Trials
5 (principal investigator on 5)
Grants
4
Labs led
2
Collaborators
266
Papers, trials and grants by year

2003: 1 trial · 2004: none · 2005: none · 2006: 2 trials · 2007: none · 2008: 1 trial · 2009: 1 trial · 2010: none · 2011: 1 paper · 2012: 4 papers · 2013: 3 papers · 2014: 7 papers · 2015: 2 papers · 2016: 4 papers · 2017: 6 papers, 1 grant · 2018: 7 papers · 2019: 6 papers · 2020: 4 papers · 2021: 5 papers · 2022: 5 papers · 2023: 3 papers, 1 grant · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers, 2 grants

Papers 50 of 63

  1. Microdosimetric characterization of proton relative biological effectiveness in pancreatic ductal adenocarcinoma cell lines. Co-author DOI 10.3389/fonc.2026.1934487↗
  2. Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment Last author DOI 10.64898/2026.07.10.737883↗
  3. Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-024-01145-0↗
  4. A spatial atlas of chemoradiation therapy in pancreatic cancer identifies cellular and microenvironmental determinants of persister populations Co-author DOI 10.1101/2025.06.20.660757↗
  5. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Co-author DOI 10.1002/cam4.7434↗
  6. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II T… Co-author DOI 10.1200/jco.24.00081↗
  7. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  8. Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes. Co-author DOI 10.1245/s10434-023-13120-3↗
  9. Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers15225355↗
  10. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Co-author DOI 10.1016/j.ctro.2021.12.012↗
  11. Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. Co-author DOI 10.1016/j.ctro.2022.04.007↗
  12. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2022.04.044↗
  13. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  14. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  15. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2020.11.006↗
  16. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Co-author DOI 10.1016/j.adro.2021.100763↗
  17. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite … Co-author DOI 10.1016/j.ctro.2021.02.004↗
  18. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  19. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  20. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cell.2020.03.062↗
  21. The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.prro.2020.02.010↗
  22. Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.radonc.2020.07.053↗
  23. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  24. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Last author DOI 10.1016/j.prro.2019.06.016↗
  25. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. Co-author DOI 10.1016/j.vgie.2019.02.009↗
  26. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  27. Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System. Co-author DOI 10.1097/mpa.0000000000001314↗
  28. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma Co-author DOI 10.1101/663583↗
  29. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. Co-author DOI 10.1172/jci.insight.126915↗
  30. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  31. Dose escalation for locally advanced pancreatic cancer: How high can we go? Co-author DOI 10.1016/j.adro.2018.07.008↗
  32. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated Wit… Co-author DOI 10.1016/j.ijrobp.2017.10.001↗
  33. Management of Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2017.12.287↗
  34. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Co-author DOI 10.1038/s41586-018-0235-7↗
  35. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Co-author DOI 10.1038/s41598-018-32159-x↗
  36. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT. Co-author DOI 10.1097/coc.0000000000000263↗
  37. A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.09.007↗
  38. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET. Co-author DOI 10.1016/j.prro.2016.09.002↗
  39. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  40. ACR Appropriateness Criteria® Resectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000370↗
  41. BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-17-0250↗
  42. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  43. Quantitative Analysis of (18)F-Fluorodeoxyglucose Positron Emission Tomography Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Ca… Co-author DOI 10.1016/j.ijrobp.2016.04.034↗
  44. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cance… Co-author DOI 10.1016/j.prro.2016.05.005↗
  45. Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000470↗
  46. A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. Last author DOI 10.1371/journal.pone.0147995↗
  47. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocar… Last author DOI 10.1002/cncr.29161↗
  48. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. First author DOI 10.1016/j.hoc.2015.04.005↗
  49. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving… Co-author DOI 10.1016/j.ijrobp.2014.02.031↗
  50. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Co-author DOI 10.1016/j.ijrobp.2014.06.066↗

Trials 5

  1. Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma Principal investigator NCT01146054↗
  2. A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreati… Principal investigator NCT01181245↗
  3. Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer Principal investigator NCT00350142↗
  4. Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx Principal investigator NCT00767273↗
  5. Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer Principal investigator NCT00233415↗

Grants 4

  1. Stem Cell Biology & Cellular Therapy Program P30CA016672↗
  2. The Role of HIF2 in Pancreatic Ductal Adenocarcinoma R01CA269565↗
  3. Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer R01CA227517↗
  4. Tumor Hypoxia: Molecular Studies and Clinical Exploitation P01CA067166↗

Closest collaborators

The 25 strongest of 266 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cullen M. Taniguchi · 14 shared papers, 2 shared grants, 2013–2026 · strength 3.56
  2. Daniel Tandel Chang · 36 shared papers, 2011–2023 · strength 2.37
  3. Eugene Jon Koay · 15 shared papers, 2018–2025 · strength 1.90
  4. Joseph M. Herman · 21 shared papers, 2012–2023 · strength 1.42
  5. Ethan Bernard Ludmir · 8 shared papers, 2021–2025 · strength 1.18
  6. Matthew H. G. Katz · 8 shared papers, 2019–2025 · strength 1.00
  7. Grace L. Smith · 7 shared papers, 2021–2024 · strength 0.89
  8. Margaret M. Kozak · 12 shared papers, 2016–2023 · strength 0.88
  9. Ching-Wei David Tzeng · 6 shared papers, 2019–2025 · strength 0.86
  10. Erqi Liu Pollom · 9 shared papers, 2014–2023 · strength 0.84
  11. Brian Matthew Wolpin · 13 shared papers, 2012–2023 · strength 0.84
  12. Robert A. Wolff · 9 shared papers, 2012–2025 · strength 0.83
  13. Tianyu Wang · 3 shared papers, 2025–2026 · strength 0.75
  14. Manoop S. Bhutani · 6 shared papers, 2019–2025 · strength 0.74
  15. Elizabeth J. Shpall · 1 shared grant, 2026 · strength 0.71
  16. Kristy Brock · 1 shared grant, 2026 · strength 0.71
  17. Dihua Yu · 1 shared grant, 2026 · strength 0.71
  18. Mien‐Chie Hung · 1 shared grant, 2026 · strength 0.71
  19. Scott Kopetz · 1 shared grant, 2026 · strength 0.71
  20. Richard Francis Dunne · 9 shared papers, 2017–2023 · strength 0.69
  21. Aram F. Hezel · 9 shared papers, 2017–2023 · strength 0.69
  22. Jonathan Andrew Nowak · 9 shared papers, 2017–2023 · strength 0.69
  23. Diego A.S. Toesca · 6 shared papers, 2017–2023 · strength 0.66
  24. Chen Yuan · 8 shared papers, 2017–2023 · strength 0.60
  25. Fada Guan · 2 shared papers, 2026 · strength 0.57

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.